Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Proteomic and genetic approaches identify Syk as an AML target.
PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups
EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism
-
Full-text index only
Backseat drivers take the wheel.
PMID 18068625 · PMC2705833 · Cancer cell · 2007 · 8 claims · 8 setups
Systematic resequencing combined with functional validation can distinguish rare driver FLT3 mutations from passenger mutations in AML patients negative for known activating mutations
-
Full-text index only
Metabolomic profiling in LRRK2-related Parkinson's disease.
PMID 19847307 · PMC2761616 · PloS one · 2009 · 7 claims · 3 setups
Metabolomic profiles of both idiopathic PD and LRRK2 PD are clearly separated from controls
-
Full-text index only
Phosphoproteomics: new insights into cellular signaling.
PMID 16168091 · PMC1242200 · Genome biology · 2005 · 8 claims · 8 setups
Protein kinases are one of the largest gene families in humans and mice, accounting for 1.7% of the human genome
-
Full-text index only
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
PMID 19015641 · PMC2633425 · Oncogene · 2009 · 8 claims · 8 setups
E884K works in concert with L858R in-cis, in a dominant fashion, to differentially alter EGFR downstream signaling and inhibitor sensitivity in an inhibitor-specific manner